3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Gynecologic
2
Dermatologic
2
Thoracic
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
pembrolizumab
69
Docetaxel
50
Nivolumab
44
Prednisone
34
enzalutamide
30
Gemcitabine
26
Cyclophosphamide
22
Cisplatin
22
Paclitaxel
21
Radiotherapy
19
Carboplatin
19
Bevacizumab
19
Abiraterone Acetate
18
Ipilimumab
17
atezolizumab
14
Magnetic Resonance Spectroscopy
14
fludarabine
13
aldesleukin
13
Sunitinib
13
Interleukin-2
12
avelumab
11
Radiosurgery
11
Pluvicto
11
Filgrastim
11
Everolimus
11
gallium 68 PSMA-11
10
fludarabine phosphate
10
enfortumab vedotin
10
durvalumab
10
cemiplimab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Solutions
×
Genitourinary
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled